BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > ECONOMY > article

[Coronavirus] Celltrion selected as priority negotiator in state project to develop treatment

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : March 19, 2020, 17:17 | Updated : March 19, 2020, 17:17
  • 트위터
  • 페이스북
  • 웨이보

[Gettyimages Bank]

SEOUL -- Celltrion, a South Korean bio firm, has been selected as preferred bidder in a state project to develop a medicine for the treatment of patients infected with a new coronavirus. South Korean scientists have developed a "unique" protein that detects antibodies to neutralize the virus.

The project involving state research bodies will be supervised by the Korea Centers for Disease Control and Prevention (KCDC), a state health agency which has been involved in a national fight to contain a coronavirus epidemic. 

Celltrion is already working on the development of antibodies with blood extracted from COVID-19 patients. The company has pledged a quick investment of some 20 billion won ($15 million) for the development of fast testing kits and medicines.

"We will do our best to secure COVID-19 therapeutic antibodies and start clinical trials in the shortest time," Celltrion Chairman Seo Jung-jin said in an online press conference on March 12. He said his company will be able to initiate clinical trials on patients in six months.

"Until COVID-19 is eradicated in South Korea, we will increase the size of clinical trials so that many patients can receive the help of drugs through clinical trials," Seo said, vowing to develop fast diagnosis kits through antibodies obtained in the press of finding the treatment of COVID-19.

"Once we have antibodies that can be bonded to the antigen of COVID-19, we can also make a diagnostic kit," he said, adding the kit would allow patients to examine themselves and check the results within 10 to 20 minutes.

Celltrion, which produces Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease,
is among a group of South Korean drug and bo companies that have jumped into the race to develop vaccines or treatments, while doctors have formed a task force to find proper treatment by mixing antiviral drugs.

Also on Thursday, Trade Minister Yoo Myung-hee visited Celltrion's head office in a free economic zone in the western port of Incheon for talks with Celltrion CEO Gi Woo-seong. Yoo said the government would actively support the quick development of Celltrion's treatment and quick diagnostic kits.


 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Researchers detect antibodies 8 months after COVID-19 infection in asymptomatic or mildly symptomatic persons.
    Researchers detect antibodies 8 months after COVID-19 infect…
  • .State watchdog starts screening Celltrions antibody treatment for COVID-19.
    State watchdog starts screening Celltrion's antibody treatme…
  • .BGF ecobio develops polylactic acid foam sheets with antiviral activities .
    BGF ecobio develops polylactic acid foam sheets with antivir…
  • .SK Bioscience ready to embark on second vaccines clinical trials.
    SK Bioscience ready to embark on second vaccine's clinical t…
  • .KCC unveils functional antiviral paint for use at multi-purpose facilities.
    KCC unveils functional antiviral paint for use at multi-purp…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • S. Korean hospital opens colonofiberscope center installed with AI medical software
  • S. Korea to develop technologies for efficient recycling of discarded batteries
  • Scientists measure important properties of solar wind
  • Samsung to release Galaxy SmartTag tracker for keys and pets
  • Hanmi Pharmaceutical unveils quick COVID-19 antigen test kit
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view